Martin Lagging
Martin Lagging
Verifierad e-postadress på medfak.gu.se
Citeras av
Citeras av
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ...
Liver International 31, 30-60, 2011
Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype
RB Ray, LM Lagging, K Meyer, R Ray
Journal of Virology 70 (7), 4438-4443, 1996
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 …
E Lawitz, E Gane, B Pearlman, E Tam, W Ghesquiere, D Guyader, L Alric, ...
The Lancet 385 (9973), 1075-1086, 2015
Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients
J Westin, H Nordlinder, M Lagging, G Norkrans, R Wejstål
Journal of hepatology 37 (6), 837-842, 2002
Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein
RB Ray, LM Lagging, K Meyer, R Steele, R Ray
Virus research 37 (3), 209-220, 1995
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ...
The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017
Interferon (IFN)–γ–inducible protein–10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic …
AI Romero, M Lagging, J Westin, AP Dhillon, LB Dustin, JM Pawlotsky, ...
The Journal of infectious diseases 194 (7), 895-903, 2006
Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection
J Westin, LM Lagging, R Wejstål, G Norkrans, AP Dhillon
Liver 19 (3), 183-187, 1999
IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection
M Lagging, AI Romero, J Westin, G Norkrans, AP Dhillon, JM Pawlotsky, ...
Hepatology 44 (6), 1617-1625, 2006
Immune responses to plasmid DNA encoding the hepatitis C virus core protein
LM Lagging, K Meyer, D Hoft, M Houghton, RB Belshe, R Ray
Journal of virology 69 (9), 5859-5863, 1995
Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection
J Westin, LM Lagging, F Spak, N Aires, E Svensson, M Lindh, AP Dhillon, ...
Journal of viral hepatitis 9 (3), 235-241, 2002
Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers
S Islam, L Antonsson, J Westin, M Lagging
Scandinavian journal of gastroenterology 40 (7), 867-872, 2005
Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
M Lagging, N Langeland, C Pedersen, M Färkkilä, MR Buhl, K Mørch, ...
Hepatology 47 (6), 1837-1845, 2008
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
S Zeuzem, JM Pawlotsky, E Lukasiewicz, M Von Wagner, I Goulis, Y Lurie, ...
Journal of hepatology 43 (2), 250-257, 2005
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
M Lagging, G Askarieh, F Negro, S Bibert, J Söderholm, J Westin, M Lindh, ...
PloS one 6 (2), e17232, 2011
Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus
LM Lagging, K Meyer, RJ Owens, R Ray
Journal of virology 72 (5), 3539-3546, 1998
Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic …
G Askarieh, Å Alsiö, P Pugnale, F Negro, C Ferrari, AU Neumann, ...
Hepatology 51 (5), 1523-1530, 2010
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C
PDC Leutscher, M Lagging, MR Buhl, C Pedersen, G Norkrans, ...
Hepatology 52 (2), 430-435, 2010
IL28B polymorphisms, IP‐10 and viral load predict virological response to therapy in chronic hepatitis C
G Fattovich, L Covolo, S Bibert, G Askarieh, M Lagging, S Clément, ...
Alimentary pharmacology & therapeutics 33 (10), 1162-1172, 2011
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial
H Orlent, BE Hansen, M Willems, JT Brouwer, R Huber, GA Kullak-Ublick, ...
Journal of hepatology 45 (4), 539-546, 2006
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20